How Much Do Patients Need to Know About a Potentially Risky Treatment?

An unapproved product made from umbilical cord blood was used at a prominent New York hospital. After an F.D.A. warning came an internal complaint: Patients should have been told.
Source: NYT Health - Category: Consumer Health News Authors: Tags: Hospitals Blood Biotechnology and Bioengineering Ethics and Official Misconduct Burst Biologics New York-Presbyterian Hospital Food and Drug Administration Surgery and Surgeons Regulation and Deregulation of Industry Medicine and Health Source Type: news